Published in Biochemistry on January 01, 1967
Subfragments from the Fc fragment of human immunoglobulin G. Isolation and physicochemical charaterization. Biochem J (1968) 2.26
The interaction between human monocytes and red cells. Specificity for IgG subclasses and IgG fragments. J Exp Med (1970) 2.05
Pepsin digestion of human G-myeloma proteins of different subclasses. I. The characteristic features of pepsin cleavage as a function of time. Clin Exp Immunol (1970) 1.50
Pepsin digestion of human G-myeloma proteins of different subclasses. II. Immunochemical investigations of the products of peptic digestion. Clin Exp Immunol (1970) 0.93
Serological specificity of IgG and IgM antiglobulin antibodies in anti-Gm(a) antisera. Clin Exp Immunol (1968) 0.90
Properties of an Fc gamma-binding protein isolated from human leukemic B cells. J Exp Med (1979) 0.90
Subfragmentation of the Fc fragment of human IgG1 myeloma protein by thermolysin. Immunology (1976) 0.88
Fb'2, a new peptic fragment of human immunoglobulin G. Biochem J (1976) 0.85
Studies on the products of peptic digestion of IgA. Immunology (1971) 0.81
Characterization of upFc, a fragment of human immunoglobulin G1 produced by pepsin in urea. Biochem J (1976) 0.78
Fragments produced by digestion of human immunoglobulin G subclasses with pepsin in urea. Biochem J (1977) 0.75
Assessing the accuracy of an automated coding system in emergency medicine. Proc AMIA Symp (2000) 2.66
Effect of gender on the obstetric-gynecologic work force. Obstet Gynecol (2001) 2.19
HIV incidence among needle exchange participants: estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr (1994) 1.84
HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr (1999) 1.72
A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr (1992) 1.65
A circulation theory of needle exchange. AIDS (1994) 1.58
CELLULAR ORIGIN OF RHEUMATOID FACTOR. J Exp Med (1959) 1.55
HIV prevalence among intravenous drug users: model-based estimates from New Haven's legal needle exchange. J Acquir Immune Defic Syndr (1992) 1.51
A decline in HIV-infected needles returned to New Haven's needle exchange program: client shift or needle exchange? Am J Public Health (1994) 1.45
On the distribution of rheumatoid factors among the immunoglobulins. Immunochemistry (1966) 1.41
The social geography of AIDS and hepatitis risk: qualitative approaches for assessing local differences in sterile-syringe access among injection drug users. Am J Public Health (2000) 1.30
Survival of HIV-1 in syringes. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.27
Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J Biol Chem (1990) 1.20
Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin Infect Dis (1998) 1.14
Detection by polymerase chain reaction of human immunodeficiency virus type 1 proviral DNA sequences in needles of injecting drug users. J Infect Dis (1992) 1.12
Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science (1979) 1.11
Prevalence and characteristics of Staphylococcus aureus in Connecticut swine and swine farmers. Zoonoses Public Health (2012) 1.10
Ectopic secretion of calcitonin by oat-cell carcinoma. N Engl J Med (1974) 1.09
HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.08
Can HIV-1-contaminated syringes be disinfected? Implications for transmission among injection drug users. J Acquir Immune Defic Syndr (2001) 1.07
Electroencephalographic sleep and mood during cocaine withdrawal. J Addict Dis (1992) 1.06
Survival of HIV-1 in syringes: effects of temperature during storage. Subst Use Misuse (2000) 1.06
Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer (1976) 1.06
Reactivity of human sera to different strains of granulocytic ehrlichiae in immunodiagnostic assays. J Infect Dis (1998) 1.06
Circulating immune complexes in sera of patients with Burkett's lymphoma and nasopharyngeal carcinoma. Int J Cancer (1976) 1.02
Inhibition of complement fixation by rheumatoid sera. Ann N Y Acad Sci (1965) 1.02
Detection of HIV-1 nucleic acid and HIV-1 antibodies in needles and syringes used for non-intravenous injection. AIDS (1998) 1.01
HIV DNA and antibodies in syringes from injecting drug users: a comparison of detection techniques. AIDS (1993) 1.01
Immunoglobulins of sheep. Arch Biochem Biophys (1969) 0.98
The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem (1981) 0.97
Serum alpha-fetoprotein in 184 Ugandan patients with hepatocellular carcinoma. Clinical, laboratory, and histopathologic correlations. Cancer (1974) 0.97
IgM and IgG anti-F(ab')2 antibodies in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum (1982) 0.97
A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients. Cancer (1975) 0.96
'Dropouts' or 'drop-ins'? Client retention and participation in New Haven's needle exchange program. Public Health Rep (1995) 0.95
Treatment of Kaposi's sarcoma with a combination of actinomycin D and vincristine. Results of a randomized clinical trial. Cancer (1973) 0.94
The immunoglobulins of sheep colostrum. Biochemistry (1969) 0.93
A latex test for the detection of human IgG aggregates and IgG anti-IgG antibody. Immunochemistry (1972) 0.93
Immunological studies in Ugandan patients with hepatocellular carcinoma. Br Med J (1973) 0.89
Amelioration of cyclophosphamide-induced cystitis. J Natl Cancer Inst (1971) 0.89
Prevalence, characteristics, and predictors of police training initiatives by US SEPs: building an evidence base for structural interventions. Drug Alcohol Depend (2011) 0.87
The measurement of IgG anti-IgG antibody in rheumatoid arthritis. J Immunol Methods (1974) 0.87
Serum hyperviscosity in Sjögren's syndrome interaction between IgG and IgG rheumatoid factor. Ann Intern Med (1974) 0.87
Prevalence of HIV-infected syringes during a syringe-exchange program. N Engl J Med (1992) 0.87
Levels of thymidylate synthetase during normal culture growth of L1210 cells. Cancer Res (1986) 0.86
Drug-using and nonusing women: potential for child abuse, child-rearing attitudes, social support, and affection for expected baby. Int J Addict (1994) 0.86
The detection of antigens in immune complexes. Scand J Immunol (1981) 0.85
The production of markers by bronchogenic carcinoma: a review. Semin Oncol (1974) 0.85
The affinity of soluble immune complexes for concanavalin A. Scand J Immunol (1978) 0.84
Hepatocellular carcinoma with the carcinoid syndrome. Cancer (1971) 0.83
Increased serum calcitonin levels in bronchogenic cancer. Chest (1976) 0.82
Syringe and needle exchange to prevent HIV infection. JAMA (1994) 0.82
Primary amyloidosis with "monoclonal" immunoglobulin A proteinemia. Am J Med (1968) 0.82
Ectopic production of calcitonin. Lancet (1973) 0.81
The hyperviscosity syndrome, polysynovitis, polymyositis and an unusual 13S serum IgG component. Am J Med (1970) 0.81
Use of bleach to disinfect HIV-1 contaminated syringes. Am Clin Lab (2001) 0.81
Specificity of IgM antibodies to pooled human F(ab')2 fragments. Immunol Commun (1984) 0.81
Effective treatment of Kaposi's sarcoma with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). Cancer Chemother Rep (1973) 0.81
Social support and anxiety in pregnant drug abusers and nonusers: unexpected findings of few differences. Drug Alcohol Depend (1993) 0.81
The surgical management of primary hepatocellular carcinoma in Uganda. Br J Surg (1973) 0.80
FC-like fragments in peptic digests of human immunoglobulin G. J Immunol (1968) 0.80
Pyrimethamine analysis by enzyme inhibition and HPLC assays. Am J Clin Pathol (1995) 0.80
IgG anti-IgG antibodies in rheumatoid arthritis and certain other conditions. Ann Rheum Dis (1974) 0.80
The specificity of antibodies to the F(ab')2 fragment of human IgG. Arthritis Rheum (1985) 0.80
Development and duration of antibody response against Ehrlichia equi in horses. J Am Vet Med Assoc (1998) 0.79
Serum alpha1-antitrypsin in patients with lung cancer or abnormal sputum cytology. Cancer (1976) 0.79
The examination of antigens in highly purified immune complexes. Immunol Commun (1979) 0.79
Elevated alpha1-Antitrypsin serum levels in lung cancer patients. Cancer (1974) 0.79
Binding of synovial fluid proteins to monosodium urate crystals in vitro. Clin Exp Rheumatol (1990) 0.78
Detecting proteoglycans immobilized on positively charged nylon. Anal Biochem (1987) 0.78
Hypercalcitonemia in bronchogenic cancer. Evidence for thyroid origin of the hormone. JAMA (1975) 0.78
Analysis of immune complexes by two-dimensional gel electrophoresis. Clin Immunol Immunopathol (1985) 0.78
Vitamin A serum and dietary vitamin A intake in lung cancer patients. Cancer Lett (1978) 0.78
Modulation of fluoropyrimidine metabolism in L1210 cells by L-alanosine. Biochem Pharmacol (1983) 0.77
Polyclonal 13S human G immunoglobulin. Purification and characterization of the G immunoglobulin causing formation of the 13S complex. Immunochemistry (1971) 0.77
Speaking the truth: an analysis of gender differences in serostatus disclosure practices among HIV-infected patients in St Petersburg, Russia. Int J STD AIDS (2012) 0.77
Proteoglycans analyzed by composite gel electrophoresis and immunoblotting. Methods Mol Biol (2001) 0.77
Serologic testing of horses for granulocytic ehrlichiosis, using indirect fluorescent antibody staining and immunoblot analysis. Am J Vet Res (1999) 0.77
Detection of glycosaminoglycans at the one-nanogram level by 125I-cytochrome c. Anal Biochem (1985) 0.76
Glycosaminoglycans and chondroitin/dermatan sulfate proteoglycans in the myocardium of a non-human primate. Matrix (1993) 0.76
Pyrazofurin enhancement of 5-azacytidine antitumor activity in L5178Y and human leukemia cells. Cancer Res (1978) 0.76
Detection of glycosaminoglycans with 125I-labeled cytochrome c. Methods Enzymol (1987) 0.76
Insulin and growth hormone response to an oral glucose load in Ugandan hepatocellular carcinoma patients. East Afr Med J (1974) 0.75
Suppressor cell dysfunction and necrotizing lesions in a child. Arch Dermatol (1981) 0.75
Cultural background and medical care. Urban Health (1984) 0.75
Uptake of 85Sr by an osteosarcoma metastatic to lung. J Nucl Med (1971) 0.75
Clinical trials of combination chemotherapy with BCNU and vincristine in the treatment of malignant melanoma in Uganda. Cancer (1973) 0.75
Mumps virus sialoadenitis. An autopsy report. Arch Pathol (1971) 0.75
[The study of characteristics of overdose among users of opioid drug injections]. Zh Nevrol Psikhiatr Im S S Korsakova (2010) 0.75
Circulating immune complexes in sera of hamsters bearing simian virus 40-induced tumours. Cancer Res (1979) 0.75
Effect of de novo purine synthesis inhibitors on 5-fluorouracil metabolism and cytotoxicity. Biochem Pharmacol (1981) 0.75
Polyclonal 13S human gamma-G immunoglobulin. J Immunol (1970) 0.75
Telangiectasia overlying malignant tumor. Arch Dermatol (1973) 0.75
Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213). Cancer Chemother Rep (1975) 0.75
Analysis of the thymidylate synthetase ternary complex by high-performance liquid steric exclusion chromatography. Anal Biochem (1981) 0.75
Blood coagulation and fibrinolysis in Ugandan patients with cirrhosis and hepatocellular carcinoma. East Afr Med J (1974) 0.75
Pitfalls in the methodology for detection of immune complexes. Surv Immunol Res (1982) 0.75
The Fd' fragment of human gamma-G immunoglobulin. Immunochemistry (1966) 0.75
Phase II clinical trials of BCNU )NSC-409962) and bleomycin (NSC-125066) in the treatment of Kaposi's sarcoma. Cancer Chemother Rep (1974) 0.75
Syndactyly in a rhesus monkey- a case report. Teratology (1972) 0.75
Lack of enhanced cytotoxicity of cultured L1210 cells using folinic acid in combination with sequential methotrexate and fluorouracil. Cancer Chemother Pharmacol (1985) 0.75